Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-B455 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BGB-B455, a putative bispecific antibody targeting CLDN6 on tumor cells and CD3 on T-cells (Mar 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-B455 | BGBB455|BGB B455 | CD3 Antibody 119 CLDN6 Antibody 10 | Limited information is currently available on BGB-B455, a putative bispecific antibody targeting CLDN6 on tumor cells and CD3 on T-cells (Mar 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06803680 | Phase I | BGB-B455 | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |